Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Nathalie I. Bouwer"'
Autor:
Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Jasper J. Brugts, Marc C. J. Kock, Jos J. E. M. Kitzen, Mark-David Levin, Eric Boersma
Publikováno v:
Cardiovascular Ultrasound, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background We aimed to study the predictive value of early two-dimensional echocardiography (2DE) speckle tracking (ST) for left ventricular ejection fraction (LVEF) changes during trastuzumab treatment for HER2-positive breast cancer. Metho
Externí odkaz:
https://doaj.org/article/bdf41c150bdb4ccc93397e29af0603f5
Autor:
Nathalie I. Bouwer, Agnes Jager, Crista Liesting, Marcel J.M. Kofflard, Jasper J. Brugts, Jos J.E.M. Kitzen, Eric Boersma, Mark-David Levin
Publikováno v:
Breast, Vol 52, Iss , Pp 33-44 (2020)
Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection f
Externí odkaz:
https://doaj.org/article/5d775c2192d24d79bd7fdf7a7678540f
Autor:
Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Sylvia M. Sprangers-van Campen, Jasper J. Brugts, Jos J. E. M. Kitzen, Michael A. Fouraux, Mark-David Levin, Eric Boersma
Publikováno v:
Cardio-Oncology, Vol 5, Iss 1, Pp 1-10 (2019)
Abstract Background Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is most widely used, is u
Externí odkaz:
https://doaj.org/article/86e45f0715864d459037753d1e848925
Autor:
Nathalie I. Bouwer, Tessa G. Steenbruggen, Hánah N. Rier, Jos J. E. M. Kitzen, Carolien H. Smorenburg, Marlies L. van Bekkum, Paul C. de Jong, Jan C. Drooger, Cynthia Holterhues, Marcel J. M. Kofflard, Eric Boersma, Gabe S. Sonke, Mark‐David Levin, Agnes Jager
Publikováno v:
International Journal of Cancer, 151(4), 616-622. Wiley-Liss Inc.
We investigated the effect of trastuzumab on cardiac function in a real-world historic cohort of patients with HER2-positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty-seven patients with HE
Autor:
Maarten J. G. Leening, Nathalie I. Bouwer, M. Arfan Ikram, Maryam Kavousi, Rikje Ruiter, Eric Boersma, Ewout-Jan van den Bos, Auke P. J. D. Weevers, Jaap W. Deckers, Mark-David Levin
Publikováno v:
European Journal of Epidemiology. Springer Netherlands
Analyses from administrative databases have suggested an increased cancer incidence among individuals who experienced a myocardial infarction, especially within the first 6 months. It remains unclear to what extent this represents an underlying biolo
Autor:
Crista Liesting, Marc C.J.M. Kock, Jasper J. Brugts, Jos J. E. M. Kitzen, Mark-David Levin, Nathalie I. Bouwer, Eric Boersma, Marcel J.M. Kofflard
Publikováno v:
Cardiovascular Ultrasound, Vol 19, Iss 1, Pp 1-11 (2021)
Cardiovascular Ultrasound, 19(1):35. BioMed Central Ltd.
Cardiovascular Ultrasound
Cardiovascular Ultrasound, 19(1):35. BioMed Central Ltd.
Cardiovascular Ultrasound
Background We aimed to study the predictive value of early two-dimensional echocardiography (2DE) speckle tracking (ST) for left ventricular ejection fraction (LVEF) changes during trastuzumab treatment for HER2-positive breast cancer. Methods HER2-p
Autor:
Carolien H. Smorenburg, Agnes Jager, Cynthia Holterhues, Tessa G Steenbruggen, Mark-David Levin, Marcel J.M. Kofflard, Hánah N. Rier, Eric Boersma, Gabe S. Sonke, Jan C. Drooger, Jos J. E. M. Kitzen, Paul de Jong, Marlies L. van Bekkum, Albert J. ten Tije, Nathalie I. Bouwer
Publikováno v:
Cancer Research. 81:PS13-21
Research objectives and rationale Trastuzumab greatly enhances the efficacy of treatment in HER2+ metastatic breast cancer (MBC). Due to its potential to induce cardiomyopathy, however, trastuzumab is contraindicated in patients with baseline left ve
Autor:
Gabe S. Sonke, Carolien H. Smorenburg, Hánah N. Rier, M-D. Levin, Tessa G Steenbruggen, Agnes Jager, Jos J. E. M. Kitzen, J. van Rosmalen, Jan C. Drooger, Nathalie I. Bouwer, Eric Boersma, A. J. Ten Tije, C Holterhues, P. C. De Jong, M. L. van Bekkum, Marcel J.M. Kofflard
Publikováno v:
Breast Cancer Research and Treatment, 186(3), 851-862. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment
Purpose Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studied a real-wo
Autor:
Aaram Omar Khader, Peter E. Westerweel, Linda H.A. de Bruin, Eske A. van Baalen, Anton W. Langerak, Eva Jansen, Mark-David Levin, Jurgen A Riedl, Paul J. Hengeveld, Ömer Balak, Nathalie I. Bouwer, Inge G.P. Geelen
Publikováno v:
British Journal of Haematology
British Journal of Haematology, 190(4), E201-E204. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 190(4), E201-E204. Wiley-Blackwell Publishing Ltd
Autor:
P. C. De Jong, Joyce Sanders, Nathalie I. Bouwer, A. J. Ten Tije, Karin Beelen, Hugo M. Horlings, Hánah N. Rier, Carolien H. Smorenburg, GS Sonke, M-D Levin, C Holterhues, Jan C. Drooger, Agnes Jager, Tessa G Steenbruggen
Publikováno v:
Cancer Research. 79:P6-17
Intro MBC is generally considered incurable, but patients with HER2+ disease treated with trastuzumab do relatively well and some have an exceptional durable response and survive over 10 years. We analyzed the clinical-pathological characteristics as